Furthermore, several randomized clinical trials investigating agents targeting EGFR, mTOR, and VEGF, along with multiple vaccine studies and immune checkpoint inhibitors, have yielded disappointing results after promising early-stage (phase I/II) studies in GBM. This evidence concerns the gene EGFR and glioblastoma.